Clinical Trials Logo

Clinical Trial Summary

The aim of this study was to evaluate safety and therapeutic response to micropulse diode 810nm laser treatment in patients with chronic central serous chorioretinopathy.


Clinical Trial Description

Most of the cases of central serous chorioretinopathy (CSC) recur spontaneously within three months of disease. After 3 months without resolution of acute CSC or in chronic CSC, continuous wave laser photocoagulation or photodynamic therapy should be considered. Direct threshold continuous photocoagulation treatment can shorten the duration of the serous detachment, but it is not appropriate for juxtafoveal or subfoveal leakage point.Subvisible photocoagulation potentially localizes and decreases chorioretinal thermic burn. Subthreshold diode micropulse (SDM) laser using a 810nm diode laser may spare the damage to the neural retina by raising the temperature of the RPE to just below the protein-denaturation threshold so that the thermal wave that reaches the neural retina is insufficient to cause neither damage nor clinically visible end-point. This therapeutic laser modality offers the possibility to minimize the iatrogenic retinal lesion. ;


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01327170
Study type Interventional
Source Federal University of São Paulo
Contact
Status Completed
Phase N/A
Start date November 2008
Completion date June 2010

See also
  Status Clinical Trial Phase
Completed NCT03497000 - Effects of OCTA-guided PDT in Acute CSC N/A
Recruiting NCT03692169 - The Changes of Retinal Capillaries After Half-dose PDT Measured by OCTA in Eyes With CSC
Not yet recruiting NCT02215330 - A Study of the Beneficial Effects of Eplerenone on Central Serous Chorioretinopathy Phase 2/Phase 3
Completed NCT01971190 - Efficacy and Safety of Intravitreal Aflibercept Injection for Subacute Central Serous Chorioretinopathy Phase 2
Completed NCT01990677 - Eplerenone for the Treatment of Central Serous Chorioretinopathy N/A
Active, not recruiting NCT01710332 - The Safety & Efficacy of Intravitreal Aflibercept Injection in Patients With Persistent Central Serous Chorioretinopathy Phase 2
Active, not recruiting NCT00403884 - Selective RPE Laser Treatment (SRT) for Various Macular Diseases N/A
Recruiting NCT05570591 - Subthreshold Nanosecond Laser for Non-resolving Central Serous Chorioretinopathy N/A
Recruiting NCT05589974 - Choroidal Blood Flow in Acute and Chronic Central Serous Chorioretinopathy
Completed NCT05104138 - Eplerenone Versus PDT: Comparative Study by OCTA
Completed NCT01880788 - Genetic Analysis of Chronic Central Serous Chorioretinopathy Masquerading as Neovascular AMD N/A
Terminated NCT01982383 - Study on the Use of Micropulse Laser to Treat Central Serous Chorioretinopathy N/A
Completed NCT01019668 - Central Serous Chorioretinopathy Treated by Modified Photodynamic Therapy N/A
Recruiting NCT06346405 - Central Serous Chorioretinopathy and Micropulse Laser Treatment
Recruiting NCT02141308 - OCT in Rare Chorioretinal Diseases
Completed NCT01822561 - Eplerenone for Central Serous Chorioretinopathy Phase 2
Completed NCT00802906 - Bevacizumab Versus Micropulse in Central Serous Chorioretinopathy (CSC) N/A
Withdrawn NCT05679180 - Navigated Microsecond Laser for Chronic Central Serous Chorioretinopathy: MICROPULSE N/A
Completed NCT05686421 - Comfortable and Stabilizing Chin & Forehead Rest Attachment for Slit Lamp Configurations N/A
Completed NCT03758963 - Selective Retina Therapy With 'R:GEN' in Patients With Central Serous Chorioretinopathy N/A